Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.
BD Announces Worldwide Voluntary Recall ofBD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems
Colleen T. White, Corporate Communications
Patricia A. Spinella, Investor Relations
FOR IMMEDIATE RELEASE – Franklin Lakes, NJ (February 8, 2010) - BD (Becton, Dickinson and Company) (NYSE:BDX) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.
The BD Q-Syte™ Luer Access device is intended for use with other infusion therapy products in the administration of fluids into the intravenous system. BD Nexiva has been added to the scope of this recall that was first initiated on Oct. 28, 2009. The BD Nexiva product has two BD Q-Syte devices within the package that could potentially be subject to the manufacturing deviation previously referenced in the Oct. 28, 2009 recall letter.
The following REF (catalog) and lot numbers, which were sold in the U.S., are included in the recall:
BD Q-Syte REF: 385100, 385101, 385102, 385108, 385150, 385151, 385164
Lot Numbers: 8268863, 8269020, 8275798, 8305510, 8305511, 8308321,
9035042, 9035044, A1967, A1979, A2056, A1950, A2399, A1951
The following REF and lot numbers, which were sold outside of the U.S., are also
included in the recall:
BD Q-Syte REF: 380510,385100,385101
Lot Numbers: 8310565,8331938,8331946,9007907,9008474,9028892
The following REF (catalog) and lot numbers of BD Nexiva were sold in the u.s and
internationally and are included in the recall:
BD Nexiva REF: 383530, 383531, 383532, 383533, 383534, 383536, 383537, 383538,
Lot Numbers: 8238450, 8248349, 8248355, 8249034, 8249035, 8259950, 8263293, 8263294,8269338,8270576,8270579,8274555,8274565,8275207,8275210,8275429,8283964,
Patient safety and the quality and safety of our products are BD's first priorities. The recall was initiated on Oct. 28, 2009 after BD received complaints due to air entry through the bottom disk of the septum. BD investigated and determined the root cause to be a manufacturing deviation. Product failures occurred on lots ofBD Q-Syte and BD Nexiva units distributed from November 2008 through November 2009. The root cause has been corrected and preventive measures, including additional inspections and preventive maintenance of the line, have been implemented.
The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa and South America.
BD has notified the U.S. Food and Drug Administration and other worldwide health agencies, as necessary, and is working with them to coordinate recall activities. Clinicians or distributors with questions can contact BD at 1-800-453-4538, option 2, extension 2585, between 8:00 AM and 5:00 PM Mountain Standard Time, Monday-Friday, or dial directly at 1-801-565-2300, x2585 or x2860.
Adverse reactions quality problems experienced with the ue of this product may be reported to FDA's MedWatch Adverse Event Reporting program either on line, by regular mail or by fax:
• On line: www.fda.gov/medwatch/report.htm
• Regular mail: Use postage-paid FDA form 3500 available at:
www.fda.gov/medwatch/getforms.htm Mail to MedWatch 5600 Fishers Lane, Rockville,
• Fax: 1-800-FDA-0178
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company
serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Neither the costs anticipated with this recall, nor the impact on BD's business, are expected to be significant. For more information, please visit www.bd.com.